Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...

Business Wire India LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, today ...

With surging crime rates, acute security staffing shortages, and mounting false alarms, organisations are desperately seeking ...

Now, more than 122 years after it was first proposed, Kamata and two other mathematicians have finally proved that a solution ...

The ASX took a hit on tariff fears with markets dropping globally. Gold soared to new highs and eyes turn to the RBA’s rate decision.

Like many tech stocks, Alphabet's (NASDAQ: GOOGL) (NASDAQ: GOOG) stock pulled back in recent months. Investors still question ...

The innovative treatment, provided by Abu Dhabi Stem Cells Center (ADSCC), in coordination with DoH and in collaboration with ...

The Department of Health - Abu Dhabi (DoH), the regulator of the healthcare sector in the emirate, has announced the ...

A radical approach to AI development is emerging that prioritizes flexibility, interoperability, and global collaboration ...

Hakimo has now raised a total of $20.5 million, including prior funding rounds led by Neotribe Ventures and Rocketship.vc.

Gemini 2.5 Pro marks a significant leap forward for Google in the foundational model race – not just in benchmarks, but in usability. Based on early experiments, benchmark data, and hands-on developer ...